Statistics

Total Visits

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients59

Select a period of time:

Number of views in the range

Views
Long-term progression-free-survival (PFS) under sunitinib (SU) treatment for metastatic renal cell carcinoma (Sulong study): Analysis of two populations - long term responders (LR) vs. primary refractory (PR) patients22

Views

Views
June 20251
July 20259
August 20251
September 20253
October 20254
November 20253
December 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil9
United States5
United Kingdom2
Argentina1
Switzerland1
Ecuador1
Kenya1
Mexico1
Uruguay1
 

Top cities views

Views
Cicero1
Fernandópolis1
Glasgow1
Goole1
Guadalupe1
Guayaquil1
Itaquaquecetuba1
Los Angeles1
Mogi das Cruzes1
Monte Grande1